Guidant Cardiac Device Gets OK

Guidant ( GDT ) said Wednesday that it had received Food and Drug Administration approval for its Vitality 2 implantable cardioverter defibrillator system.

The Vitality 2 is the company's latest version of its existing device designed to treat patients at risk for sudden cardiac death as a result of an irregular heartbeat. The company said a full market launch is scheduled for May.

The Indianapolis medical device maker said sudden cardiac death claims the lives of as many as 460,000 people a year in the U.S. alone.

Guidant previewed first-quarter earnings on Tuesday, saying revenue would reach $934 million, slightly above the consensus estimate of analysts polled by Thomson One Analytics. In addition, the company guided in line with the Wall Street consensus EPS of 55 cents.

The company reports official quarterly results April 22.

Shares fell 88 cents, or 1.3%, to $67.26.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain